RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker.

Br J Cancer · 2009 · PMC2634715 · PMID 19165202

Europe PMC DOI

hedged sentences

0.0550

closest p · 1.1× alpha

0.1940

boldest claim

The sentences

showed a trendP =0.055so close (0.05 < p ≤ 0.1)

A subset analysis of stage 3 patients showed a trend associating poor survival with serum RASSF1A methylation ( P =0.055), although the data were limited due to the small number of patients in the subgroup.

also in 53,322 other papers

did not reach statistical significanceP =0.194not close (p > 0.1)

In multivariate analysis of survival, methylation of RASSF1A in serum had a hazard ratio of 2.4 (95% CI, 0.6–9.2), although this association did not reach statistical significance ( P =0.194).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.